Hi [[ session.user.profile.firstName ]]

Corning Scientific Seminar Series

  • Date
  • Rating
  • Views
  • Short Tutorial: Techniques for Harvesting Adherent Cells
    Short Tutorial: Techniques for Harvesting Adherent Cells Corning Life Sciences Recorded: Jun 18 2018 5 mins
    Harvesting your cells is an important step in maintaining healthy cultures. Good technique will lead to a healthy single cell suspension. There are many harvesting options depending on the cell line and application. In this video, we will discuss some tips/tricks to harvesting cells.
  • Short Tutorial: Corning® Matrigel® Matrix: Thin Coating Method Best Practices
    Short Tutorial: Corning® Matrigel® Matrix: Thin Coating Method Best Practices Corning Life Sciences Recorded: Jun 4 2018 3 mins
    Looking for tips using Matrigel matrix before you coat and plate your cells? We’ve got you covered. Watch our short tutorial for best practices on how to coat Matrigel Matrix as a thin gel layer.
    In search of more Matrigel matrix user information? We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thin, Non-gelled Protein Layer Method
    Short Tutorial: Corning® Matrigel® Matrix: Thin, Non-gelled Protein Layer Method Corning Life Sciences Recorded: Jun 4 2018 3 mins
    Trying to use Matrigel matrix for cell attachment? Watch our short video to learn the best way to coat Matrigel matrix in a thin, non-gelled protein layer.
    Interested in some more Matrigel matrix best practices? We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thick Coat Method Best Practices
    Short Tutorial: Corning® Matrigel® Matrix: Thick Coat Method Best Practices Corning Life Sciences Recorded: Jun 4 2018 3 mins
    Did you know that cells can be cultured inside Matrigel matrix? Learn more about the “thick-coating” method to embed cells in a 3D, more in vivo-like environment.
    Looking for more great Matrigel Matrix tips and tricks? We’ve summarized a bunch in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • Short Tutorial: Corning® Matrigel® Matrix: Thawing Best Practices
    Short Tutorial: Corning® Matrigel® Matrix: Thawing Best Practices Corning Life Sciences Recorded: Jun 1 2018 3 mins
    We get a lot of questions on the best ways to thaw Matrigel matrix. Are the color changes normal? What are the best ways to ensure homogeneity? Get the answers to these questions and other best practices for effectively thawing the most widely used ECM in research, Corning Matrigel Matrix. We’ve summarized some other great tips and tricks for Matrigel in our newly published "Ultimate Guide to Matrigel Matrix" – download it today: https://goo.gl/9Nq5Td
  • 最新技術  Corning®可溶性マイクロキャリアの培養システムを初公開
    最新技術 Corning®可溶性マイクロキャリアの培養システムを初公開 コーニングインターナショナル株式会社 ライフサイエンス事業部 石渡孝至 Recorded: May 29 2018 30 mins
    シングルユース技術導入ポイントとなる効果的な細胞培養と分離工程の簡素化を実現するアプリケーションをMSC(間葉系幹細胞)を例に概説します。
  • 3D Imaging of 3D Cell Culture Models
    3D Imaging of 3D Cell Culture Models Tom Villani, Ph.D., Ann Rossi, Ph.D. Recorded: May 17 2018 60 mins
    One of the obstacles to working with 3D cell cultures is how to extract meaningful data from them. To address this problem, Visikol has developed their Visikol® HISTO-M™ tissue clearing reagent that allows for complete 3D cell culture characterization using confocal imaging or a 3-fold increase in cells detected using wide-field microscopy. This tissue clearing approach has been developed to be rapid and compatible with multi-well plates so that it can be conducted using automated pipetting robots and high content confocal imaging systems.
    By attending this webinar you will learn about:
    • Methods to enable 3D cell culture
    • Ways to enhance imaging and characterization of 3D spheroids

    Presenter Bios:
    Dr. Tom Villani is the CSO and Co-founder of Visikol Inc and is responsible for the companies scientific strategy. Since launching Visikol with Co-Founders Dr. Michael Johnson and Nick Crider, Dr. Villani has led the development of the Visikol HISTO tissue clearing technology for three-dimensional tissue imaging as well as a suite of digital pathology tools. Visikol has leveraged these technologies in its 3Screen service offering where the company is focused on transforming tissues into actionable insights as a service for primarily pharmaceutical companies.

    Dr. Ann Rossi graduated from the University of Rochester School of Medicine and Dentistry with a Ph.D. in Pharmacology and received postdoctoral training at the University of Chicago. Prior to joining Corning, Ann worked as a Senior Scientist at ARMGO Pharma, Inc., a small private pharmaceutical company, contributing her expertise in calcium signaling toward developing new assays for the company’s screening cascade. Ann is new to Corning Life Sciences as the Applications Lab Manager in Kennebunk, Maine and is drawing on her strong academic and industry research experience to direct the activities of the applications group.
  • OncoCilAir™: A 3D human in vitro model for lung cancer research
    OncoCilAir™: A 3D human in vitro model for lung cancer research Samuel Constant, PhD, Co-founder, CEO Recorded: Nov 2 2017 38 mins
    In this special webinar, our guest presenter Samuel Constant Ph.D., Co-founder, CEO for OncoTheis will review:

    - Novel in vitro tests for modelling lung cancer
    - A model that allows long term monitoring of toxicity or efficacy on respiratory tract
    - How OncoCilAir™ is a 3D human airway epithelium with tumors reconstituted in vitro

    Abstract:
    With more than 1 million deaths worldwide per year, lung cancer remains an area of unmet needs. Realistic human 3D models are required to improve preclinical predictivity. To that end, OncoTheis has engineered a novel in vitro lung cancer model, OncoCilAir™, which combines a functional reconstituted human airway epithelium, human lung fibroblasts and lung adenocarcinoma cell lines. Because of its unique lifespan (>3 month) and its dual composition (healthy and cancerous human tissues), OncoCilAir™ allows for the concurrent testing of the efficacy of drug candidates against malignant cells and their non-toxicity against healthy tissues. Accordingly, a first proof of concept study performed on a panel of anti-cancer drugs including the investigational drugs selumetinib and Mekinist® demonstrated that OncoCilAir™ carrying the KRASG12S mutation showed responsiveness in agreement with first clinical reported results, validating this unique tissue model as a predictive tool for anticancer drug efficacy evaluation. OncoTheis has now extended the model to EGFR mutations. Results showed that OncoCilAir™ EGFRdel19 is sensitive to Tarceva® and Iressa® treatments and provides a useful model to decipher in vitro mechanisms of resistance.
  • Modeling NAFLD and TGFβ-induced Fibrosis in 3D Bioprinted Human Liver Tissue
    Modeling NAFLD and TGFβ-induced Fibrosis in 3D Bioprinted Human Liver Tissue Jeff Irelan, Ph.D. Recorded: Oct 5 2017 52 mins
    We hope you join us for this special webinar. Jeff Irelan, Director of Scientific Applications for Organovo will be our guest presenter.

    Abstract:
    Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to become the leading indication for liver transplant by 2025. Despite decades of research focused on NAFLD, an effective treatment has yet to be approved. This is due in part to the reliance on cell culture and animal models that present challenges in translation due to limited functional longevity and species differences, respectively.

    ExVive™ 3D Bioprinted Human Liver Tissue, a clinically-translatable in vitro model, is ideal for studying the effects of drugs on liver disease progression, regression, and the mechanisms involved. Here, we present results showing a nutrient overload induction of liver disease and TGFβ-induced fibrosis in ExVive™ Human Liver Tissue. A variety of disease-relevant phenotypes including steatosis, inflammation, and fibrosis can be demonstrated in the model:
    •Nutrient overload leads to the accumulation of lipid droplets in hepatocytes.
    •Incorporation of Kupffer cells and stimulation induces inflammatory cytokine release.
    •Chronic exposure to nutrient overload leads to stellate cell activation and fibrosis.
    •Chronic exposure to chemical inducers of fibrosis or TGFβ stimulation leads to stellate cell activation and fibrosis.
    •A TGFβR1 kinase inhibitor effectively blocks TGFβ-induced fibrosis.

    Presenter Bio:
    Jeff Irelan holds a Ph.D. in molecular biology from the University of Oregon. As Director of Scientific Applications, Jeff interfaces with Organovo’s customers and R&D team to implement and expand the company’s portfolio of service offerings utilizing bioprinted tissue models.
  • New Technologies for Cellular Research: 3-Dimensional Cell Culture and Screening
    New Technologies for Cellular Research: 3-Dimensional Cell Culture and Screening Richard M. Eglen, Ph.D Recorded: Sep 22 2017 54 mins
    It is now recognized that target and compound identification, as well as validation, are better conducted using cells with physiologically relevant phenotypes and genotypes. This assertion has accelerated the adoption of primary cells, stem cells, or patient-specific cells in cellular research, in general; and drug discovery, in particular.

    Technological improvements in three-dimensional (3D) cell culture technology, as a means to better mimic in vivo physiology, have accelerated recently—not only in the areas of cancer and neurological research, but also for the assessment of compound metabolic and toxicological liabilities. Furthermore, 3D cell culture can provide novel approaches to the scale-up and manufacture of biologically based medicines, including those used in immuno-and stem cell-based therapies.

    In this presentation, the existing and future impact of 3D cell culture technology on fundamental research, and drug discovery and manufacture will be addressed, particularly in the context of using phenotypically relevant cells. Specifically, it will discuss the potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development.

    Future directions will also be covered, including organs-on-chips, hydrostatic flow technologies, microfluidics, and 3D bioprinting. Some of these approaches will allow for real-time observation of cellular responsiveness to novel compounds and drugs … boldly taking the researcher into a fourth dimension of 3D cell culture!

Embed in website or blog